Voyager Acquisition Corp. Reports $8.99M Net Income, Plans Merger with Veraxa Biotech AG

Voyager Acquisition Corp., a blank check company incorporated in the Cayman Islands, reported a net income of $8.99 million for the fiscal year ending December 31, 2025, compared to $4.14 million in the previous year. The increase in profitability was primarily driven by interest income from investments held in a trust account, which rose to $10.76 million from $4.68 million in 2024. The company has not yet generated any operating revenues, as it is still in the process of seeking a business combination. As of December 31, 2025, Voyager had total assets of approximately $270.06 million, with $269.86 million held in a trust account.

The company has made significant strides in its strategic development, particularly with its planned business combination with Veraxa Biotech AG, a Swiss company. This agreement, entered into on April 22, 2025, outlines a two-step merger process that is expected to close in the first quarter of 2026, pending shareholder approval and other customary conditions. The merger is anticipated to enhance Voyager's position in the healthcare sector, aligning with its management team's expertise in this industry.

Operationally, Voyager has maintained a steady headcount of three executive officers and has not yet hired any full-time employees. The company has focused on leveraging its management team's extensive network and experience to identify potential acquisition targets. As of the end of 2025, Voyager had 25.3 million Class A ordinary shares and 6.3 million Class B ordinary shares outstanding. The company’s shares are listed on Nasdaq, and it has not paid any dividends to date, as it aims to complete its initial business combination before considering such distributions.

The filing also highlighted potential risks and uncertainties that could impact Voyager's future operations, including economic volatility, geopolitical instability, and the competitive landscape for business combinations. The company has until August 12, 2026, to complete its initial business combination, or it will be required to liquidate. Management has expressed confidence in its ability to identify and execute a successful business combination, although it acknowledges the inherent challenges in the current market environment.

Looking ahead, Voyager Acquisition Corp. aims to utilize the funds held in its trust account to facilitate its business combination and support the operations of the target company post-merger. The company is actively preparing for the upcoming shareholder vote on the proposed merger with Veraxa, which is a critical step in its strategic plan to enhance shareholder value and establish a foothold in the healthcare sector.